A-Portfolio

The company in one breath

Hims & Hers Health, ticker HIMS on the New York Stock Exchange, sells recurring online care for weight loss, hair loss, sexual health, mental health, and other conditions people would rather handle from a couch than a waiting room.

Customers pay for access to clinicians, treatment plans, medicine, and follow-up care. The pitch is simple: make healthcare feel like a clean consumer app. Good would look like customers staying for years, adding treatments, and trusting the platform even when the drug menu changes.

Why now

The stock closed at $27.72 on October 14, down 6.7% that day. That means the market erased almost two dollars per share in one session and left the stock far below its old highs. Good entry quality would look like the business proving its next act before the price runs away again.

The business is moving faster than the stock. Hers launched hair-loss care in the United Kingdom on October 14 after expanding women’s health services in Australia. Hers now supplies more than 40% of U.S. revenue and recently passed a $1 billion annual revenue pace. That means the women’s brand has become a real growth engine, not pink paint on the original men’s business. Good would look like the same products winning overseas without marketing costs swallowing the new sales.

The next exam lands on November 9, when Hims & Hers reports third-quarter results. Management expects $880 million to $900 million of revenue, which means roughly 18% sequential growth at the midpoint from the second quarter. Good would look like at least $900 million, an adjusted operating profit margin above 10%, and free cash flow back above zero.

Peptides add gasoline and a lit match. Management plans to offer legally manufacturable treatments such as sermorelin, glutathione, and NAD+, while other products still depend on final Food and Drug Administration rules. Good would look like a narrow, compliant launch backed by human evidence. Selling hype in a syringe would be a fast way to turn a healthcare brand into a courtroom hobby.

The numbers, translated

• Second-quarter revenue was $753.2 million, up 38%. Revenue is the money customers paid before expenses. Good for a company at this scale would look like growth above 25%, so the top line clears the bar.
• Subscribers reached 2.89 million, up 19%. Subscribers are customers who agreed to recurring billing. Good would look like growth above 15% without promotions doing all the lifting, so this also clears the bar.
• Monthly revenue per average subscriber reached $92, up 21%. That measures how much the average customer spends each month. Good would look like this rising alongside subscriber count, because more customers spending more is stronger than squeezing a shrinking crowd.
• Gross margin fell to 64% from 76%. Gross margin is what remains from each sales dollar after paying for medicine, fulfillment, and direct service costs. Hims kept 64 cents, down from 76 cents. Good would look like at least 68 cents as branded weight-loss drugs and international sales grow.
• Gross profit rose only 15.5% while revenue rose 38%. Gross profit is the dollar pile available to pay staff, advertising, technology, and everything else. Good would look like gross profit growing closer to revenue, not less than half as fast.
• The quarter produced an $86.3 million net loss after a $42.5 million profit one year earlier. Net income is the final score after every expense. Good would look like a return to profit without management asking us to ignore half the expense list.
• Free cash flow was negative $68.2 million. Free cash flow is the cash left after running the business and buying the equipment and software it needs. Good would look like positive cash generation in the third quarter and for the full year.
• Marketing consumed $262.2 million, or 34.8% of revenue. That means almost 35 cents from each sales dollar went toward finding and keeping customers. Good would look below 30 cents while subscriber growth stays above 15%.
• Cash and short-term investments totaled $841.0 million, while convertible notes totaled $1.37 billion. Convertible notes are debt that may later turn into shares. Good would look like the company funding growth from operations instead of adding debt or issuing more stock.
• The share count rose 2.7% in six months. That means each existing share owned a slightly smaller slice of the company. Good would look below 2% a year, not above that pace in half a year.
• At $27.72, the current shares carry a market value near $6.47 billion. Market value is the price of all current shares. After adding debt and subtracting cash and short-term investments, the operating business costs about $6.99 billion, or 2.18 times the midpoint of management’s 2026 sales forecast. Good would look below 2 times sales until margins stop falling.

What I like

The brand reaches people who hate the old healthcare maze. The company turned awkward conditions into recurring relationships, then widened those relationships into weight loss, women’s health, diagnostics, and international care. Good would look like the platform selling a second specialty to existing customers, because the cheapest customer to acquire is the one already inside.

The growth is real. Revenue, subscribers, and spending per subscriber all rose together. That combination says Hims & Hers is not merely buying empty accounts. Good would look like domestic revenue growth accelerating from the latest 16% while the acquired international businesses add growth without hiding weakness at home.

Distribution may be the moat. Hims & Hers does not invent Wegovy or Ozempic, which belong to Novo Nordisk (NVO), but it can put approved treatments in front of millions of consumers quickly. Good would look like drugmakers treating the platform as a preferred storefront instead of a regulatory headache.

The crowd understands the opportunity and the danger. Thirty-day research found 18 Reddit threads with 755 upvotes and two YouTube videos with 14,279 views. One investor wrote that the hard part is already built, meaning the clinician network and distribution. Another answered the international expansion with, “Just gonna get sued again...” Good would look like the first comment becoming the business model and the second staying a joke.

What worries me

The margin collapse is not cosmetic. Revenue grew 38%, but gross profit grew only 15.5%. That means the newest sales carry much less economic muscle. Good would look like management proving that branded drugs bring longer customer lives or profitable add-on care, not just impressive revenue with a skinny wallet.

The company keeps asking investors to grade an adjusted score. Adjusted operating profit was $60.3 million, but the standard-accounting net result was an $86.3 million loss. Good would look like both measures turning positive together. If the “adjusted” version keeps winning while cash leaves, the adjustment is doing the heavy lifting.

Regulation can rewrite the product shelf overnight. Hims & Hers settled with Novo Nordisk and now offers approved GLP-1 drugs, but peptide access still depends on rules that can change. Good would look like every new treatment surviving legal, safety, and evidence checks before launch. Fast is useful. Fast and sloppy gets expensive.

The balance sheet is bigger and messier after acquisitions. Goodwill, the accounting value assigned to acquired businesses beyond their hard assets, jumped to $1.10 billion from $278.3 million in six months. Good would look like those businesses producing durable cash. Bad acquisitions turn goodwill into a future write-down, which is accounting’s way of admitting the wedding was overpriced.

The crowd signal is bullish but concentrated. A separate tracker counted 38 finance-subreddit mentions, with 66% bullish, yet most came from one very enthusiastic corner. Good would look like customers, clinicians, and independent healthcare analysts confirming the story, not only stockholders cheering each other from the same booth.

What would make this a buy

My position size is zero. This is research and commentary, never a buy signal.

I want the November 9 report to deliver at least $900 million of revenue, an adjusted operating profit margin above 10%, and positive free cash flow. Those three tests would show that growth, profit, and cash can share the same room. Good would also include gross margin at 65% or better, because another sharp drop would tell me the new revenue is too thin.

I want domestic revenue growth above 20%, subscriber growth above 18%, and monthly revenue per subscriber holding at least $90. That would prove the core U.S. engine is strengthening while international expansion adds fuel. Good is both engines running, not one towing the other.

Price matters. At $24, the operating business would cost roughly 1.91 times the midpoint of 2026 sales guidance. That means the valuation would fall below my 2 times sales line while still giving the company credit for strong growth. I would rather pay after clean proof at $24 than chase a peptide headline at $30.

What makes me walk away

I walk if third-quarter revenue misses $880 million. That is the bottom of management’s own range, so missing it would mean the promised reacceleration failed its first public test.

I walk if gross margin drops below 62% or free cash flow stays worse than negative $68 million. That would mean growth keeps consuming economics and cash instead of creating them.

I walk if management launches a peptide before the legal pathway and human safety evidence can carry the claim. Healthcare trust takes years to build and one ugly shortcut to burn.

I walk if share growth exceeds 5% a year, debt rises again, or an acquisition produces another giant goodwill jump without cash profit. Growth bought with dilution and debt can make revenue look heroic while each share gets weaker.

IPO Watch

• Iambic Therapeutics (IAM), expected to begin Nasdaq trading October 15 after pricing at $16. It sold 9.375 million shares and raised $150 million before fees, which means the company now has fresh cash for AI-designed cancer drugs. Good would look like its lead HER2 drug producing meaningful human tumor responses without ugly safety problems.
• City Therapeutics, private, proposed ticker CTY, expected October 16 at $17 to $19. It develops RNA-interference drugs that switch off disease-causing proteins. The range tells us what IPO buyers may pay before trading starts. Good would look like its lead program beating existing gene-silencing treatments on durability, safety, or convenience while the IPO cash lasts through important human data.

The verdict

Score: 76 out of 100. Bucket: watch. Hims & Hers earned points for brand strength, 38% revenue growth, nearly 2.9 million subscribers, rising customer spending, broad recurring-care potential, founder-led execution, international expansion, and a reasonable sales valuation after the stock’s fall.

It lost points because gross margin fell 12 percentage points, standard-accounting profit turned into an $86.3 million loss, free cash flow stayed negative, marketing ate almost 35% of revenue, debt exceeds liquid assets, the share count is rising, acquisitions inflated goodwill, and regulators still control too much of the next product chapter. Candidate status starts at 80. HIMS misses by four because the growth machine works, but the cash machine needs a wrench.

The DBTech read

Gross margin tells you how much of each sales dollar survives the direct cost of delivering the product. Hims & Hers kept 64 cents from each second-quarter dollar, down from 76 cents a year earlier. Revenue can grow while the business weakens if every new dollar arrives with less profit attached. Good growth expands the sales pile without crushing the amount kept. A packed restaurant means less when every new table orders the loss-leader.

Sources and as-of date

• Price: $27.72 at 4:00 p.m. Eastern on October 14, 2026, the latest completed regular-session close, with a $29.26 open, $29.68 high, $27.57 low, and about 11.0 million shares traded, Yahoo Finance and Exa Markets. Retrieved at 7:02 a.m. Eastern on October 15, 2026. Read-only Robinhood price and option-chain tools were unavailable in this run, so no contract, fill, bid, ask, or Greek is assumed.
• Revenue, subscribers, monthly revenue per subscriber, margins, losses, cash flow, guidance, marketing, stock pay, balance sheet, debt, acquisitions, and share count: Hims & Hers second-quarter results and June 2026 Form 10-Q, filed August 10, 2026.
• Next earnings date: Hims & Hers investor relations, announced October 12, 2026.
• UK and Australia expansion: Hims & Hers newsroom and UK launch announcement, published October 14, 2026.
• GLP-1 partnership and peptide context: Hims & Hers, Reuters on the Novo Nordisk agreement, and Reuters on peptides, retrieved October 15, 2026.
• IPO calendar and terms: Iambic Therapeutics, City Therapeutics preliminary prospectus, and IPOScoop, retrieved October 15, 2026. Dates can move until trading starts.
• Community research covered September 15 through October 15, 2026. It returned 18 Reddit threads, two YouTube videos, three Hacker News stories, and three GitHub items. X was unavailable and YouTube transcripts failed, so the crowd evidence is useful but incomplete. Raw research: workspace/newsletters/a-portfolio/research/hims-hers-health-hims-raw-v3.md.
• Calculations use decimal arithmetic, the $27.72 close, 233,297,933 shares, $841.0 million of cash and short-term investments, $1.365 billion of convertible notes, and the $3.2 billion midpoint of 2026 revenue guidance. Research and commentary only, never a buy signal.